BCG vaccine of 2004 the vaccine is given to about 100 million children per year globally. The main use of BCG is for vaccination against tuberculosis. BCG vaccine can be administered after birth intradermally. BCG vaccination can cause a false positive Mantoux test, although a very high-grade reading is usually due to active disease. The most controversial aspect of BCG is the variable efficacy found in different clinical trials, which appears to depend on geography. Trials conducted in the UK have consistently shown a protective effect of 60 to 80%, but those conducted elsewhere have shown no protective effect, and efficacy appears
Abell 1201 BCG than expected from the usual scaling relations between black holes and host galaxies. However, alternative methods of modelling the stellar velocity dispersion maps reveals an ambiguity between the UMBH mass and the dark halo profile. In solutions where the UMBH is more massive, the dark matter is more cuspy. In solutions where the UMBH is smaller or absent, the dark matter is more cored. The dark halo's ellipticity and the mass-to-light ratio of stars also enter the ambiguity. Thus, if the standard computational models are robust, then Abell 1201 BCG presents a dilemma and a challenge to either the conventional